Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

NCT04713046 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

HPV 16+ Recurrent or Metastatic Cancer

Interventions

BIOLOGICAL: CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16
BIOLOGICAL: Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]